Randall L, Xiang Y, Matsumoto T, Giannarelli D, et al. Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. Gynecol Oncol 2025;199:88-95.
PMID: 40592026